Biocause Pharma(SZ:000627) 证券时报·2025-09-28 11:22Core Viewpoint - *ST Tianmao (000627) has announced its decision to voluntarily delist its shares from the Shenzhen Stock Exchange, with the delisting set to occur on September 30, 2025 [2][5]. Group 1: Delisting Announcement - On September 28, *ST Tianmao received a notice from the Shenzhen Stock Exchange regarding the termination of its stock listing [2]. - The company submitted its application for voluntary delisting on September 10, 2025, which was officially accepted by the exchange [5]. - The decision to delist was approved during the company's board meeting on August 8, where it was resolved to withdraw its A-share listing [5]. Group 2: Post-Delisting Arrangements - After the delisting, *ST Tianmao's shares will be transferred to the National Equities Exchange and Quotations (NEEQ) for management in the delisted segment [3]. - The company has provided investors with a cash option for their shares, with an exercise price set at 1.60 CNY per share [8]. - Approximately 1.442 billion cash options were effectively declared during the cash option application period, and the settlement for these options has been completed [8]. Group 3: Shareholder Information - As of July 18, 2025, *ST Tianmao had a total of 112,000 shareholders [9]. - The last trading price before the suspension was 1.58 CNY per share, giving the company a market capitalization of approximately 7.7 billion CNY [9].